上海交通大学学报（医学版）

上海交通大学学报（医学版）

• 论著（基础研究） • 上一篇    下一篇

吉西他滨联合索拉非尼对胆囊癌细胞生长侵袭的抑制作用

秦一雨，周学平*，林培艺，陈志升，吕立升，汤朝晖   

  1. 上海交通大学  医学院附属新华医院普外科， 上海 200092
  • 出版日期:2014-03-28 发布日期:2014-04-02
  • 通讯作者: 汤朝晖, 电子信箱: tangzhaohui@yahoo.com。
  • 作者简介:秦一雨（1983—）， 男， 主治医师， 博士; 电子信箱: vajviv@163.com; 周学平（1970—）， 男， 副主任医师， 博士; 电子信箱xp05zhou@163.com； *为共同第一作者。
  • 基金资助:

    上海市教委科研创新重点项目（2011ZZ107）

Inhibitory effects of combination of gemcitabine with sorafenib on proliferation and invasion of gallbladder cancer cells

QIN Yi-yu, ZHOU Xue-ping*, LIN Pei-yi, CHEN Zhi-sheng, LÜ Li-sheng, TANG Zhao-hui   

  1. Department of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
  • Online:2014-03-28 Published:2014-04-02
  • Supported by:

    Innovation Program of Shanghai Municipal Education Committee，2011ZZ107

PDF (PC)

1028

摘要：

目的 评估吉西他滨和索拉非尼联合用药对胆囊癌细胞株SGC996生长、凋亡、迁移和侵袭的影响。方法 采用吉西他滨和索拉非尼单独或联合处理SGC996细胞，吉西他滨单独处理组浓度分别为0.1、1.0、2.0、4.0和10.0 μg/mL；索拉非尼单独处理组浓度分别为0.1、1.0、2.5、5.0、10.0和20.0 μmol/L；两药联合处理组：索拉非尼浓度分别为2.5、5.0、10.0和20.0 μmol/L，吉西他滨浓度分别为2.0、4.0和10.0 μg/mL。未经药物处理的SGC996细胞作为空白对照组。采用MTT法检测SGC996细胞的生长状况；应用Transwell实验检测SGC996细胞的迁移和侵袭能力。应用FITC-Annexin V/PI双染法检测SGC996细胞的凋亡率。结果 索拉非尼可抑制SGC996细胞生长，并且这种抑制作用具有浓度和时间依赖性（P<0.05）；同时还可抑制SGC996细胞的迁移和侵袭（P<0.05），但不诱导细胞凋亡（P>0.05）。吉西他滨对SGC996细胞的生长和迁移并无显著抑制作用（P>0.05），但可以抑制细胞的侵袭，并诱导细胞凋亡（P<0.05）。索拉非尼和吉西他滨联合用药可以抑制SGC996细胞的生长、迁移和侵袭，并诱导细胞凋亡（P<0.05）。结论 吉西他滨和索拉非尼联合用药对胆囊癌细胞的抑制作用显著强于单独用药，可能成为治疗胆囊癌的有效化疗方案。

关键词: 吉西他滨, 索拉非尼, 胆囊癌

Abstract:

Objective To evaluate the effects of gemcitabine combined with sorafenib on the proliferation, apoptosis, migration, and invasion of gallbladder cancer cell line SGC996. Methods The cells were treated with gemcitabine and/or sorafenib. The concentrations of the group treated with gemcitabine were 0.1, 1.0, 2.0, 4.0, and 10.0 μg/mL. The concentrations of the group treated with sorafenib were 0.1, 1.0, 2.5, 5.0, 10.0, and 20.0 μmol/L. The concentrations of the group treated with gemcitabine and sorafenib were as follows: gemcitabine (2.0, 4.0, and 10.0 μg/mL) and sorafenib (2.5, 5.0, 10.0, and 20.0 μmol/L). The cells of control group were not treated with gemcitabine or sorafenib. The proliferation of SGC996 cells was examined by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The migration and invasion of SGC996 cells were examined using Transwell assay. The apoptosis of SGC996 cells was examined by FITC-Annexin V/PI double staining. Results Sorafenib inhibited the proliferation of SGC996 cells, and this growth inhibition was dependent on time and dose (P<0.05). Sorafenib also inhibited migration and invasion of SGC996 cells (P<0.05), but it did not induce apoptosis (P>0.05). Gemcitabine induced apoptosis and inhibited invasion of SGC996 cells (P<0.05), but it did not inhibit proliferation and migration of SGC996 cells (P>0.05).The combination of gemcitabine and sorafenib induced apoptosis of SGC996 cells and significantly inhibited the proliferation, migration, and invasion of SGC996 cells (P<0.05). Conclusion The antitumor ability of combination of gemcitabine and sorafenib is much higher than that of either gemcitabine or sorafenib, which may be an effective chemical therapy for gallbladder cancer.

Key words: gemcitabine, sorafenib, gallbladder cancer